Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2022-01-25 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
Regulatory Filings Classification · 100% confidence The document is a press release dated January 25, 2022, announcing a new drug discovery partnership between Evotec SE and Boehringer Ingelheim in ophthalmology. It details the nature of the agreement, financial terms (undisclosed upfront, FTE payments, milestones, royalties), and includes standard corporate boilerplate and contact information. This type of announcement, which is not a formal periodic report (like 10-K or IR), a specific financial event (like DIV or CAP), or a management change (MANG), falls best under a general regulatory announcement or news release. Since it is a specific corporate action/news item disseminated via DGAP (a service often used for regulatory news), and it doesn't fit the definitions for ER (Earnings Release), LTR (Legal), or TAR (M&A), the most appropriate general category for significant, non-periodic corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements.
2022-01-25 English
Correction of a release from 22/11/2021, 12:30 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights'. It details a 'Type of capital measure' involving a 'Conditional capital increase' and an 'Other capital measure' under German Securities Trading Act (WpHG) sections, resulting in a new total number of voting rights (176,608,195). This content directly relates to changes in the company's capital structure and voting rights, which aligns best with the 'Capital/Financing Update' (CAP) category, as it announces a change related to capital measures. Although it involves voting rights, it is not the result of a shareholder vote (DVA) but rather a regulatory disclosure about the capital base itself. Given the focus on capital increase and total rights, CAP is the most precise fit.
2022-01-20 English
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
Regulatory Filings Classification · 100% confidence The document is a news release dated January 18, 2022, announcing a drug discovery collaboration between Evotec SE and Eli Lilly and Company regarding metabolic diseases. It details the terms, potential value, and strategic rationale. The header 'DGAP-News' and the structure strongly suggest a corporate press release or regulatory news service announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific shareholder/management filing, it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is disseminated via DGAP, a service for regulatory announcements and corporate news.
2022-01-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Notification of Major Holdings' and explicitly discusses the 'Acquisition/disposal of shares with voting rights' by Allianz Global Investors GmbH, detailing the change in percentage of voting rights from 4.94% to 2.997%. This content directly corresponds to regulatory filings concerning changes in significant share ownership thresholds. Among the provided definitions, 'Major Shareholding Notification' (Code: MRQ) is the most accurate fit for reporting changes in significant share ownership levels crossing thresholds, as indicated by the structure and content of the filing (which resembles a German WpHG notification regarding voting rights changes). Although it is a regulatory announcement, MRQ is more specific than the general RNS fallback.
2022-01-12 English
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
Regulatory Filings Classification · 100% confidence The document is a news release dated January 11, 2022, announcing an expansion of a collaboration between Evotec SE and Bristol Myers Squibb regarding neurodegeneration research and targeted protein degradation. It details financial considerations (payments received) and strategic updates. This type of announcement, which is a corporate update disseminated via a news service (DGAP/EQS Group AG), does not fit the specific definitions for formal financial reports (10-K, IR, ER, AR) or shareholder materials (DEF 14A, AGM-R). Since it is a general corporate announcement that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2022-01-11 English
DGAP-DD: Evotec SE english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and details a transaction (Acquisition) by a person discharging managerial responsibilities (Dr. Werner Lanthaler, Member of the managing body) in the company's shares. This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2022-01-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.